Clascoterone (Breezula) for Hair Loss: The First New Drug Class in 30 Years?

A man I hear from regularly uses finasteride but has spent two years quietly dreading the day it stops being enough. He’s not alone. That dread has a name in the research community, and clascoterone is the first serious answer to it in three decades.

Related on the Blueprint: DHT and Male Pattern Baldness and Dutasteride vs Finasteride.

Let me be upfront about what that means and what it doesn’t. Clascoterone, marketed under the brand name Breezula for the scalp indication and already FDA-approved as Winlevi 1% cream for acne, is a topical androgen receptor antagonist. It doesn’t interfere with how your body makes DHT. Instead, it goes straight to the scalp and competes with DHT at the receptor itself. No DHT signal, no miniaturization signal. The mechanism is different from anything currently approved for androgenetic alopecia (AGA), which is exactly why the hair-loss community is paying attention.^[1]

Phase 3 data from the SCALP-1 and SCALP-2 trials, 1,465 men across the US and Europe, came out with headline numbers that look extraordinary. Up to 539% relative improvement in Target Area Hair Count versus placebo in one trial. Those numbers need unpacking, honestly, because they are not what they first sound like.

How it works: blocking DHT at the door

The existing treatments work upstream. Finasteride and dutasteride block the enzyme (5-alpha-reductase) that converts testosterone into DHT. Minoxidil is a vasodilator, something of a blunt instrument that encourages blood flow and keeps follicles in the growth phase longer. Neither approach touches the androgen receptor directly.

Clascoterone sits at the receptor and physically competes with DHT for the binding site. DHT arrives, finds the slot taken, and the miniaturization signal never fires. That’s the entire idea. The critical engineering detail: when you apply it to the scalp, it metabolizes locally into inactive compounds before it reaches systemic circulation in meaningful amounts. So you get the androgen blockade where you want it, without suppressing testosterone or DHT body-wide.^[2]

This matters to a particular group of men: those who want the anti-androgen effect at the follicle but are worried about systemic side effects from DHT suppression. Clascoterone is designed to give you one without the other. Whether that promise holds in the real world is the question the Phase 3 program was built to answer.^[3]

The Phase 3 trials: what the numbers actually say

The SCALP-1 and SCALP-2 trials enrolled 1,465 men, 18 and older, across US and European sites. The treatment was clascoterone 5% solution applied twice daily. The primary endpoint was Target Area Hair Count (TAHC), the standard measure in AGA trials: a photo-documented count of hairs in a defined area, baseline versus endpoint at six months.

Cosmo Pharmaceuticals released the topline data: up to 539% relative improvement in TAHC versus placebo in SCALP-1, and 168% relative improvement in SCALP-2.^[1] Let me be direct about what those percentages mean, because “539% improvement” sounds like a miracle and it isn’t.

“Relative improvement versus placebo” is a ratio. If the placebo group loses 5 hairs and the treatment group gains 10, the relative improvement is not 10 hairs, it’s the treatment-versus-placebo difference expressed as a multiple of the placebo change. Placebo groups in AGA trials often shed slowly, so dividing a modest absolute gain by a small negative denominator produces impressive-looking percentages. 539% relative improvement doesn’t mean hair quintupled. It means the treatment arm did substantially better than placebo did, expressed as a multiplier on a small placebo move.

Here’s my analogy for this. Imagine you’re racing someone, and you run 102 meters while they run 100. You’re 2% faster. Now imagine the race track was slightly downhill for them and they still only ran 98 meters. Relative to their performance, you did 539% better, in some constructions. The absolute distance you covered was 102 meters. That’s still real progress, it just isn’t the number being headlined.

The second thing worth flagging: 539% in one trial and 168% in the other. That’s a factor-of-three difference between two trials run on the same drug at the same dose. Both are positive. Both favor clascoterone. But that kind of gap tells you something: either the trials enrolled different severity of hair loss, had different placebo trajectories, or the effect size is genuinely variable from population to population. Probably some combination. A drug with a variable effect is still a useful drug, but it’s one you go into with calibrated expectations.^[4]

Safety looked favorable in both trials. Minimal skin irritation was the primary adverse event reported. No significant systemic side effects. That’s what the mechanistic story would predict: if the drug breaks down locally, you don’t get systemic anti-androgen effects.^[2]

Where clascoterone fits in the landscape

The approved treatments for AGA have been finasteride (FDA, 1997), dutasteride (approved for AGA in South Korea and Japan, off-label in the US), and minoxidil (FDA-approved topically, and now available orally off-label). All three were either discovered or approved in the 1980s and 1990s. Clascoterone, if it reaches approval, would be the first genuinely new mechanism: not a 5-alpha-reductase inhibitor, not a vasodilator. An androgen receptor antagonist applied locally. Thirty years is a long time to wait for a new idea.

Some readers will recognize a parallel immediately: RU58841. That’s a topical anti-androgen that’s been popular in the hair-loss community for years, with compelling animal data and a rabid following among DIY experimenters. The conceptual overlap is real. Both are topical, both compete at the androgen receptor. The difference that actually matters: clascoterone ran two large Phase 3 registered trials with 1,465 participants, submitted to regulatory oversight, and reported the results. RU58841 has no Phase 3 data. No safety database. That’s not a minor procedural distinction. It’s the difference between a drug and a research chemical. If clascoterone gets approved, men will have a vetted, manufactured, consistently-dosed topical AR antagonist for the first time ever.^[3]

The timeline toward approval

As of spring 2026, the 12-month safety follow-up from the SCALP trials is completing. That’s the critical data package: a regulatory agency wants to see not just that a drug worked at six months, but that nothing unexpected showed up over a year of continuous use. Assuming the safety data holds, the regulatory dossier would go in, and we’re looking at potential US and EU approval in the 2027 range. Not a guarantee. But a realistic window.^[1]

Breezula already has a market identity (clascoterone is already approved as Winlevi for acne, so the manufacturing, the molecule’s safety profile in humans, and the regulatory pathway are not starting from zero). That matters for approval timelines. It’s a much shorter road to prove a new indication when the drug already has a safety record in a different approved product.

My read on all of this

What I’d watch for in the full data release: the absolute hair count numbers (not just the relative percentages), whether the trial populations differed in ways that explain the SCALP-1 versus SCALP-2 gap, and how the 12-month safety data shakes out. The six-month safety profile looked clean. A year is better evidence.

There’s also the combination question. Clascoterone blocks DHT at the receptor. Finasteride reduces how much DHT reaches the follicle in the first place. They’re not redundant: one works upstream, one works at the target. Whether layering them provides additive benefit isn’t established by Phase 3 data yet, but it’s the obvious next research question and worth keeping an eye on at philippeb.pro as the field moves forward.

What men should realistically expect

If you’re tracking this because you’re weighing your options right now: clascoterone isn’t available for AGA yet. Winlevi (clascoterone 1%) exists for acne, but the 5% scalp formulation (Breezula) is still completing its regulatory path. Don’t expect 2027 to feel like a sudden unlock: approval happens, then prescribers need to learn about it, then insurance and access logistics follow. Real-world availability lags approval by months to a year in practice.

Use the waiting time to understand the options clearly. Finasteride and minoxidil are proven. They’re not exciting, but they work for most men who start early and stay consistent. Clascoterone looks like a meaningful addition, particularly for men who’ve avoided finasteride over systemic concerns. It’s not a replacement for everything we have. It’s a new category. The field needed one.^[4]

The hair-loss treatment space has been running on two mechanisms for 30 years. That’s not because the problem was solved. It’s because drug development is hard and AGA was deprioritized. Clascoterone landing in Phase 3 with positive data is genuinely notable, whatever the final approval verdict turns out to be.